Tumefactive demyelinating lesion
Citation, DOI & article data
Tumefactive demyelinating lesion (TDL), also sometimes referred to as monofocal acute inflammatory demyelination (MAID), is a locally aggressive form of demyelination, usually manifesting as a solitary lesion (or sometimes a couple of lesions) greater than 2 cm that may mimic a neoplasm on imaging.
On imaging, they usually present with relatively little mass effect or surrounding edema, contrast enhancement in an open-ring pattern, high ADC values, and low relative cerebral blood volume (rCBV).
As is the case with multiple sclerosis, and other demyelinating diseases, tumefactive demyelination is most frequently encountered in women, usually young middle age (average onset at 37 years of age) 3.
Unlike acute disseminated encephalomyelitis (ADEM), tumefactive demyelinating lesions are usually not post-infective. Additionally, although patients with multiple sclerosis can develop large tumefactive demyelinating plaques (which have very similar appearances - see tumefactive multiple sclerosis), patients who present with a solitary tumefactive demyelinating lesion infrequently go on to develop multiple sclerosis (MS) 3.
Patients present with symptoms atypical for multiple sclerosis such as focal neurologic deficits, seizures, and/or aphasia 5. Most do not progress to multiple sclerosis 6. In some instances, patients can deteriorate rapidly and succumb to illness (e.g. acute malignant Marburg variant of MS).
Tumefactive demyelinating lesions appear as a large hypoattenuating lesion with ill-defined ring enhancement, central necrosis, perilesional edema and minimal mass effect 7.
The International Magnetic Resonance Imaging in MS Collaboration categorizes the different MRI appearances of tumefactive demyelination:
Tumefactive demyelinating lesions tend to be large but with relatively little mass effect or surrounding edema. Centrally located dilated veins have also been observed within these lesions 1,9.
T1 C+ (Gd)
- about half of tumefactive demyelinating lesions demonstrate contrast enhancement 2
- the enhancement pattern is usually in the form on an open ring and the incomplete portion of the ring is on the grey matter side of the lesion 4
- perfusion imaging
diffusion imaging (DWI)
- can be less helpful in differentiating tumefactive demyelinating lesions from tumors, as necrotic neoplasms may display a similar increase in apparent diffusion coefficient (ADC)
- however, diffusion imaging can help differentiate ring-enhancing tumefactive demyelinating lesions from cerebral abscesses
- while the former show mildly increased ADC, the latter demonstrate restricted diffusion 3
- beta, gamma glutamate/glutamine (β,γ-Glx) has been shown to be specific to tumefactive demyelinating lesions 11
- elevation of choline and lactate are supportive of tumefactive MS, but not specific 9
- the pattern can otherwise be indistinguishable from that of neoplasms (decreased NAA/Cr ratio, increased Cho/Cr ratio, and variable lactate and lipid peaks)
General imaging differential considerations include:
- high-grade glioma (e.g. GBM)
- enhancement is usually a complete ring around central necrosis
- prominent surrounding vasogenic edema
- may have non-enhancing tumor
- vivid usually solid enhancement, without central non-enhancement (except sometimes in immunocompromised individuals)
- cerebral infective process: cerebritis or cerebral abscess
- restricted diffusion prominent in central liquid component
- often there is no evidence of established multiple sclerosis, and many patients do not go onto to develop MS
- tumefactive demyelination is not necessarily benign, and patients can have a fulminant course ending in demise (e.g. Marburg variant of MS)
- lesions are centered on white matter and involve subcortical U-fibers
- less mass effect than expected for size
- incomplete leading edge enhancement is characteristic
- CBV is lower than in tumors
- 1. Cha S, Pierce S, Knopp EA et-al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol. 22 (6): 1109-16. AJNR Am J Neuroradiol (citation) - Pubmed citation
- 2. Dagher AP, Smirniotopoulos J. Tumefactive demyelinating lesions. Neuroradiology. 1996;38 (6): 560-5. - Pubmed citation
- 3. Given CA, Stevens BS, Lee C. The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol. 2004;182 (1): 195-9. AJR Am J Roentgenol (citation) - Pubmed citation
- 4. Masdeu JC, Moreira J, Trasi S et-al. The open ring. A new imaging sign in demyelinating disease. J Neuroimaging. 1996;6 (2): 104-7. - Pubmed citation
- 5. Paley RJ, Persing JA, Doctor A et-al. Multiple sclerosis and brain tumor: a diagnostic challenge. J Emerg Med. 7 (3): 241-4. - Pubmed citation
- 6. Saindane AM, Cha S, Law M et-al. Proton MR spectroscopy of tumefactive demyelinating lesions. AJNR Am J Neuroradiol. 2002;23 (8): 1378-86. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 7. Fallah A, Banglawala S, Ebrahim S et-al. Case Series: tumefactive demyelinating lesions: a diagnostic challenge. Can J Surg. 2010;53 (1): 69-70. Free text at pubmed - Pubmed citation
- 8. Gutrecht JA, Berger JR, Jones RH et-al. Monofocal acute inflammatory Demyelination (MAID): a unique disorder simulating brain neoplasm. South. Med. J. 2002;95 (10): 1180-6. Pubmed citation
- 9. Sarbu N, Shih RY, Jones RV et-al. White Matter Diseases with Radiologic-Pathologic Correlation. Radiographics. 2016;36 (5): 1426-47. doi:10.1148/rg.2016160031 - Pubmed citation
- 10. Seewann A, Enzinger C, Filippi M, Barkhof F, Rovira A, Gass A, Miller D, Montalban X, Thompson A, Yousry T, Tintore M, de Stefano N, Palace J, Rovaris M, Polman C, Fazekas F. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. Journal of neurology. 255 (1): 1-10. doi:10.1007/s00415-007-0754-x - Pubmed
- 11. Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. (2007) AJNR. American journal of neuroradiology. 28 (2): 272-7. Pubmed